Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. (Nasdaq: RVMD) generates frequent news as a late-stage clinical oncology company advancing a pipeline of RAS(ON) inhibitors for RAS-addicted cancers. Its public announcements highlight clinical trial milestones, regulatory designations and corporate developments related to drug candidates such as daraxonrasib, elironrasib and zoldonrasib.
News coverage for RVMD often centers on clinical data readouts and trial progress. The company has reported results from studies of daraxonrasib in metastatic pancreatic ductal adenocarcinoma (PDAC) in both previously treated and first-line settings, as well as combination regimens with gemcitabine and nab-paclitaxel. It also releases updates on global Phase 3 trials, including RASolute 302 and 304 in PDAC and RASolve 301 in RAS-mutant non-small cell lung cancer (NSCLC).
Another key news theme is regulatory interaction with the U.S. Food and Drug Administration. Revolution Medicines has announced FDA Breakthrough Therapy Designations for daraxonrasib, elironrasib and zoldonrasib in specific KRAS-mutant NSCLC and pancreatic cancer settings, Orphan Drug Designation for daraxonrasib in pancreatic cancer, and a Commissioner’s National Priority Voucher for daraxonrasib. These items are frequently covered in press releases and investor communications.
Investors and observers can also expect corporate and financial updates, including quarterly financial results, strategic financing transactions such as the Royalty Purchase Agreement with Royalty Pharma, and leadership appointments to support late-stage development and potential commercialization. Conference presentations at major healthcare and oncology meetings, where the company shares updated clinical and preclinical data, are another recurring source of news.
This news page aggregates such disclosures, offering a centralized view of Revolution Medicines’ clinical progress, regulatory milestones and corporate events for those tracking RVMD’s development in RAS-driven oncology.
Revolution Medicines (Nasdaq: RVMD), focusing on targeted therapies for RAS-addicted cancers, will participate in the Guggenheim Healthcare Talks 2022 Oncology Conference. CEO Mark A. Goldsmith will lead a fireside chat, scheduled for 12:30 p.m. Pacific on February 10, 2022, during the virtual event from February 9-11, 2022. Interested parties can access the live webcast and a subsequent replay on the company's Events & Presentations page. Revolution Medicines is advancing its R&D pipeline with various RAS(ON) inhibitors and RAS Companion Inhibitors.
Revolution Medicines (RVMD) reported significant advancements in its RAS(ON) Inhibitor pipeline during the J.P. Morgan Healthcare Conference. The company has dosed the first patient in a Phase 2 trial combining RMC-4630 with Lumakras™ for advanced non-small cell lung cancer. Two new drug candidates, RMC-9805 and RMC-8839, are set for IND filings in 2023. Initial results for RMC-5552 indicate encouraging activity in treating advanced tumors. Overall, the updates reflect strong momentum in addressing unmet medical needs for RAS-addicted cancers.
Revolution Medicines (RVMD) announced that CEO Mark A. Goldsmith will present at the 40th Annual J.P. Morgan Healthcare Conference from January 10-13, 2022. The presentation, scheduled for January 11 at 2:15 p.m. ET, will focus on the expansion of the company’s RAS(ON) Inhibitors pipeline, specifically RMC-6236 and RMC-6291, alongside updates on clinical-stage RAS Companion Inhibitors RMC-4630 and RMC-5552. Investors can access the live webcast through the company’s website and a replay will be available for 14 days post-conference.
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company, will participate in the 4th Annual Evercore ISI HealthCONx Conference from November 30 to December 2, 2021. Mark A. Goldsmith, M.D., Ph.D., CEO and chairman, will join a fireside chat on December 2 at 11:45 a.m. Eastern. The event will be virtual, with a live webcast available on Revolution Medicines’ website, where a replay will be accessible for 14 days post-conference. The company focuses on developing targeted therapies for RAS-addicted cancers, with various RAS(ON) and Companion Inhibitors in its R&D pipeline.
Revolution Medicines, Inc. (Nasdaq: RVMD) reported its financial results for Q3 2021, highlighting significant advancements in its RAS(ON) Inhibitor pipeline. The company continues to progress candidates RMC-6291 (KRASG12C) and RMC-6236 (RASMULTI), with plans to select another development candidate by year-end. Preclinical data show RMC-6291's superior anti-tumor activity compared to adagrasib. However, total revenue fell to $1.1 million from $12.7 million YoY, influenced by an $8.5 million non-cash adjustment. The net loss increased to $52.9 million, with a full-year guidance net loss projected between $170 million and $190 million.
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company, will participate in the Stifel 2021 Virtual Healthcare Conference from November 15-17, 2021. CEO Mark A. Goldsmith will engage in a fireside chat on November 15 at 2:40 p.m. Eastern. The company focuses on developing drugs that target RAS-addicted cancers through innovative drug discovery capabilities. Its R&D pipeline features RAS(ON) Inhibitors like RMC-6291 and RMC-6236, along with various RAS Companion Inhibitors, aimed at enhancing cancer treatment strategies.
Revolution Medicines, Inc. (RVMD) will announce its third quarter 2021 financial results on November 10, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET, led by senior management discussing financials and corporate developments. The company focuses on precision oncology, developing targeted therapies for RAS-addicted cancers. Their R&D pipeline includes RAS(ON) Inhibitors like RMC-6291 and RMC-6236, and RAS Companion Inhibitors such as RMC-4630. The live webcast and archives can be accessed on their website.
Revolution Medicines announced an invited oral presentation at the upcoming AACR-NCI-EORTC Virtual International Conference, showcasing preclinical data from its RAS(ON) inhibitor programs. Scheduled for October 9, 2021, the session will feature Steve Kelsey, M.D., presenting on the discovery and development of RAS(ON) inhibitors targeting various oncogenic RAS variants. This highlights the company's ongoing efforts in developing targeted therapies for RAS-addicted cancers.
Revolution Medicines (Nasdaq: RVMD) announced its participation in the 3rd Annual RAS-Targeted Drug Development Summit from September 21-23, 2021. Key presentations include:
- Targeting KRASG12C(ON) by Bob Nichols, Ph.D. on September 22 at 11:55 a.m. Eastern.
- Combination Strategies for RAS-Addicted Cancers by Jan Smith, Ph.D. on September 22 at 2:00 p.m. Eastern.
- Panel discussion moderated by Steve Kelsey, M.D. on September 23 at 4:15 p.m. Eastern.
The Company focuses on developing targeted therapies for RAS-addicted cancers.
Revolution Medicines, a clinical-stage oncology company (Nasdaq: RVMD), announced that CEO Mark A. Goldsmith will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. Eastern Time. The conference runs from September 13-15, 2021, in a virtual format with a live webcast accessible on the company’s website. Revolution Medicines specializes in developing targeted therapies for RAS-addicted cancers, with its R&D pipeline including RAS(ON) Inhibitors and RAS Companion Inhibitors.